Exagen Inc. (XGN)

Exagen Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Exagen Inc. (XGN) is a Medical - Diagnostics & Research company based in US with a market capitalization of $119.6M. Revenue grew 19.6% year-over-year and free cash flow was negative at -$14.3M. This page tracks XGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 209 employees · IPO Sep 19, 2019

Valuation

Valuation & price

$3.64as of May 17, 2026· -69.6% vs 52w high

P/E ratio

Latest-FY diluted EPS

6.85

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$11.92$7.30$2.68Jul 25Dec 25Jul 26
$2.6552-week range$11.96
Loading valuation history…

Fundamentals

Key fundamentals

$119.6M

Market cap

19.6%

Revenue growth (YoY)

58.3%

Gross margin

-$14.3M

Free cash flow (USD)

-$26.8M

Net debt

Net cash position

18.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20152025

$17.9M$66.6M

Free cash flow by year

20152025

-$12.7M-$14.3M

Gross margin by year

20212025

57.4%58.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 9, 2026Filing

    Annual Meeting Results

  • 8-K eventMay 11, 2026Filing

    Earnings Release

  • Quarterly reportMay 11, 2026Filing

    10-Q Filed

  • 8-K eventApr 23, 2026Filing

    Director Resignation

Questions

Frequently asked questions

What is Exagen Inc.'s market cap?

Exagen Inc. (XGN) has a market capitalization of $119.6M.

What is XGN's P/E ratio?

A meaningful P/E ratio is not available for XGN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is XGN's price-to-book (P/B) ratio?

XGN trades at 6.85 times book value per share.

Are insiders buying XGN stock?

SEC Form 4 filings show no open-market insider buys at Exagen Inc. in the last 90 days (0 sells).

Same arena

Related companies in Medical - Diagnostics & Research

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.